Status: M&A
Amunix focuses on immuno-oncology, leveraging proprietary and clinically validated PRO-XTEN™ technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. They aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity.
Amunix addresses this challenge by using their universal, protease-releasable masking technology (PRO-XTEN), to create next generation, conditionally active TCEs (XPAT® proteins) and cytokines (XPAC™ proteins), that are preferentially activated in tumors as compared to healthy tissues.
Amunix was acquired by Sanofi (EPA: SAN) in 2022.
To learn more, please visit: www.amunix.com